The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332
Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.
Last update: 04/11/2021
There are currently 26 open trials
Escalating doses of RO7425781 for relapsed and/or refractory myeloma
This trial is investigating whether a drug called RO7425781 is safe and effective for the treatment of relapsed and/or refractory myeloma patients.
RO7425781 is a new type of immunotherapy being tested for the treatment of myeloma. It works by helping your immune cells find and kill myeloma cells.
The trial will consist of two parts.
Part A will test increasing doses to identify the best dose level, safety and efficacy.
Part B will use the results of optimum dosing from part A for a larger group of patients.
University College Hospital, London
Who can enter the study?:
Relapsed and/or refractory myeloma patients who have previously received treatment with an immunomodulatory agent, such as lenalidomide (Revlimid®), and a proteasome inhibitor such as bortezomib (Velcade®), and are now intolerant to standard-of-care treatment.
Patients will be assigned to receive intravenous infusion (into the vein) or subcutaneous injection (under the skin) of RO7425781.
Different groups of patients will be given different doses of the drug.
Patients will be required to attend outpatient clinics for regular check-ups and blood tests. Patients will have to attend follow-up appointments for up to 69 weeks.
(for Medical Professionals):
This is a first-in-human, open-label, uncontrolled, multicenter, dose-escalation and expansion Phase I study. The study is
designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of RO7425781 in patients with
relapsed/refractory myeloma, for whom no standard-of-care treatment exists or who are intolerant to those established
For more information, click here.